Loading...

Purified anti-human CD279 (PD-1) Antibody

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, PDCD1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
EH12dot2H7_Pure_022508
PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with purified CD279 (clone EH12.2H7) (filled histogram), or purified mouse IgG1, κ (open histogram), followed by anti-mouse IgG FITC.
  • EH12dot2H7_Pure_022508
    PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with purified CD279 (clone EH12.2H7) (filled histogram), or purified mouse IgG1, κ (open histogram), followed by anti-mouse IgG FITC.
Cat # Size Price Quantity Check Availability Save
329902 100 µg 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
Block, IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  2. Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed
  3. Kim A, et al. 2019. J Immunol. 203:1076. PubMed
  4. Del Alcazar D, et al. 2019. Cell Rep. 28:3047. PubMed
  5. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  6. Gee MH, et al. 2018. Cell. 172:549. PubMed
  7. Kim MH, et al. 2018. Cancer Immunol Res. 0.427083333. PubMed
  8. Hsu DC, et al. 2018. Clin Infect Dis. 67:437. PubMed
  9. Lewinsky H, et al. 2018. J Clin Invest. 128:5465. PubMed
  10. Stervbo U, et al. 2019. Front Immunol. 0.949305556. PubMed
  11. Enyindah-Asonye G, et al. 2019. Front Immunol. 10:511. PubMed
  12. Lu X, et al. 2018. Am J Cancer Res. 8:1564. PubMed
  13. Zahn R, et al. 2008. J Virol. 82:11577. PubMed
  14. Vojnov L, et al. 2010. J Virol. 84:753. PubMed
  15. Conrad J, et al. 2011. J Immunol. 186:6871. PubMed
  16. Monteiro P, et al. 2011. J Immunol. 186:4618. PubMed
  17. Conrad J, et al. 2012. J Virol. 86:4213. PubMed
  18. Nicholas K, et al. 2015. Cytometry A. 10.1002/cyto.a.22799. PubMed
  19. Tang X, et al. 2020. Sci Adv. 6:eaaz0374. PubMed
  20. Dhariwala MO, et al. 2020. Cell Rep Med. 1:100132. PubMed
  21. Gernoux G, et al. 2020. Mol Ther. 28:747. PubMed
  22. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  23. Schwabenland M, et al. 2021. Immunity. . PubMed
  24. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  25. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  26. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  27. Mirzaei R, et al. 2021. Sci Adv. 7:eabh2148. PubMed
  28. Chakhtoura M, et al. 2021. PLoS Pathog. 17:e1009732. PubMed
  29. Stensland ZC, et al. 2022. iScience. 25:103626. PubMed
  30. Saber MM, et al. 2022. Antibodies (Basel). 11:. PubMed
  31. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  32. Liu F, et al. 2020. J Immunother Cancer. 8:. PubMed
  33. Dean JW, et al. 2020. J Autoimmun. 108:102417. PubMed
  34. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  35. Macmillan ML, et al. 2021. Blood Adv. 5:1425. PubMed
  36. Anna F, et al. 2021. J Immunother Cancer. 9:. PubMed
  37. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
  38. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  39. Hwang HJ, et al. 2021. Immun Inflamm Dis. 9:274. PubMed
  40. Cobb DA, et al. 2022. J Immunother Cancer. 10:. PubMed
  41. Kondo H, et al. 2022. Front Immunol. 13:836923. PubMed
  42. Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed
  43. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  44. Leader AM, et al. 2021. Cancer Cell. 39:1594. PubMed
  45. McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed
RRID
AB_940488 (BioLegend Cat. No. 329902)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org
Go To Top Version: 6    Revision Date: 08.25.2022

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account